Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank god $NEXI resumed. First time I've seen T12 resume same day. Didn't want to lose sleep over this for months. Phewwww😅 https://t.co/SkkpJMAyM4 pic.twitter.com/u2dfjHIvXD
— madaz (@madaznfootballr) December 1, 2023
NEXI: CONGRATS to ya, Boss!!! Bet you scored HUGE!!!
NEXI: CONGRATS on your profits here!!!
No reason this should’ve gone to 11 nor seeing this trade in the 7s
Bots bots bots
Safe to say intraday shorts are getting roasted and buying to cover
And if this didn’t get the t12 earlier robots could’ve taken this to $25
Good old algo’s
No clue who’s buying here
Scary
not this time LOL
I am shocked to see it resumed so fast
im sure many are relieved
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 30, 2023, NexImmune, Inc. (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based upon Nasdaq’s review of the Company and pursuant to Nasdaq Listing Rule 5101, Nasdaq believes that the Company is a “public shell,” and that the continued listing of its securities is no longer warranted. Nasdaq’s notice also provides that, unless the Company timely appeals Nasdaq’s determination, it would be subject to delisting. Accordingly, the Company intends to timely request a hearing. The hearing request will automatically stay any suspension or delisting action pending the hearing. There can be no assurance that the Company will ultimately be able to demonstrate compliance with all applicable listing criteria.
$NEXI https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173096261&txt2find=t12%20halt
ADDED TO THE SHIT LIST
$EDTX $GGAA $CREC $RACY $GRCY $MEOA $ASPA
Yep, saw this morning the squeeze, lmao..not sure if same will happen to Siox( another announced liquidation but haven’t yet???)…and a group shorted TaRa, could be same peeps???
Thats what manipulators get ! Now they take the L
Meaning 'REST IN PEACE' (RIP??)
Friday was collected, with a slight increase, maybe the start of a nice increase.
imho
NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
February 16 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida.
AIM ACT T cells are non-engineered CTLs against 5 multiple myeloma antigen-peptide targets and include subtype populations (Tscm, Tcm, Tem) associated with anti-tumor activity and immunologic memory. The abstract describes the ability of multi-TAA AIM ACT T cells to work synergistically with BiTE therapy, revealing several important advantages over endogenous TAA nonspecific CD8 T cells + BiTE. The results show that BiTE potency, as measured by a reduction in tumor burden in vivo, is markedly increased in the presence of AIM T cells. Importantly, following withdrawal of BiTE therapy, recipients of the AIM ACT T cell combination remained tumor free or had a low tumor burden, while those that had received the bulk CD8+ T cell combination died within two weeks. This observation strongly suggests that AIM ACT T cells provide immunosurveillance following the withdrawal of the BiTE, a distinct advantage over bulk CD8+ T cells, which should contribute to the maintenance of remission.
“Our preclinical findings hold the promise that clinically, the AIM multi-TAA specific T cells can significantly enhance the activity of BiTEs over the current standard of care and also provide immunosurveillance, potentially helping extension and maintenance of remission in patients,” said Principal Investigator, Johannes Zakrzewski, M.D., Associate Member of the Center for Discovery and Innovation at Hackensack University Medical Center.
Abstract details:
Title: Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy
Lead Authors: Mark Batistick, Center for Discovery and Innovation, Hackensack Meridian Health
Abstract #:
Date/Time: 22061
February 16, 2023 at 5:45 pm ET (virtual poster presentation)
About NexImmune
NexImmune is a clinical stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities. NexImmune is focused on developing injectable AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology, autoimmune disorders and infectious diseases.
For more information, visit www.neximmune.com.
Forward Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to managem
$NEXI: Bounces to $0.32 here
Recovery with all the other small cap bios today.
Nice lil 33% move on the day
GO $NEXI
Burning through 20 mill in cash per quarter with 40 mill in cash and no revenue, R/S and/or share registration likely soon
https://www.otcmarkets.com/filing/html?id=16019595&guid=ovz-k6lorYfaEch
Soon I think “4:19p ET 8/15/2022 - Benzinga
NexImmune Highlights FDA Clearance Of IND For NEXI-003 For The Treatment Of HPV-Related Cancers
Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancers
Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22
Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22
Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.”
Another great stock with imo a perfect chart set up, product, services, revenue and communications … down 95% from 12 month highs, when is this market going to wake up
Nice news today!
$NEXI Added some AH..
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
First IND for NexImmune’s AIM nanoparticle platform in solid tumors
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers
GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, has received IND clearance for the Company’s first cellular therapy product candidate addressing solid tumors. NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), is being developed for patients with relapsed or refractory human papillomavirus (HPV)-related cancers.
Kristi Jones, NexImmune’s CEO, commented, “The FDA clearance of our third IND marks another significant milestone for NexImmune and demonstrates our team’s continued focus and commitment to bringing novel therapies to patients with significant unmet need. NEXI-003 is our third T cell therapy and first candidate to address solid tumors. NEXI-003 consists of T cell populations simultaneously directed against multiple HPV tumor-relevant antigen targets. The T cells in our product candidate will consist of T cell subtypes critical to both potential anti-tumor activity and a phenotype intended to produce long-term immunologic memory required for durable responses.”
The Phase 1 trial will enroll patients at multiple clinical sites across the United States. The proposed study is a two-part, multicenter, open-label, dose-finding, first-in-human (FIH) study to characterize the safety and clinical activity of NexImmune’s HPV tumor-relevant antigen-specific CD8+ T cell product candidate (NEXI-003) in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers (with confirmed histopathology detection of HPV-16 and/or HPV-18 expression), who have received at least 1 prior regimen of standard therapy according to local standard of care guidance(s). The dose escalation phase will consist of multiple safety cohorts investigating increasing doses of NEXI-003 followed by an expansion phase that will enroll 24 to 36 patients overall, depending on the number of dose escalations. All patients will be followed for at least one year. Following initial data and after the recommended Phase 2 dose has been confirmed, NexImmune plans to expand the NEXI-003 development program to include other HPV related malignancies and evaluate potential SOC combination options across the patient populations.
About HPV-Related Cancers
Human papillomavirus (HPV)-related cancers are common epithelial malignancies that account for approximately 5% of all cancers globally. These cancers cause an estimated 12,500 deaths each year in the United States and more than 300,000 deaths each year throughout the world. Histologically, this family of cancers consists of squamous cell carcinomas and adenocarcinomas that occur in various anatomical sites including the oropharynx, uterine cervix, anus, vagina, vulva and penis. The high-risk HPV subtypes are most commonly HPV-16 and HPV-18. Malignant transformation results through the activation of the expression of the E6 and E7 HPV oncogenes, which inhibit the tumor suppressors p53 and Rb. These oncoproteins also inhibit apoptosis of tumor cells, deregulate the cell cycle, result in the accumulation of genetic instability, promote angiogenesis and facilitate the invasiveness and metastatic spread of cancerous cells.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least three prior lines of therapy, respective
Recent NXEN News
Quarterly Report (10-q) • Edgar (US Regulatory) • 05/12/2022 04:36:26 PM
Quarterly Report (10-q) • Edgar (US Regulatory) • 02/08/2022 11:08:49 AM
Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/31/2022 08:56:58 PM
Current Report Filing (8-k) • Edgar (US Regulatory) • 01/21/2022 06:05:12 PM
Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/29/2021 05:23:53 PM
Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 11/29/2021 05:21:02 PM
Quarterly Report (10-q) • Edgar (US Regulatory) • 11/22/2021 02:57:38 PM
Annual Report (10-k) • Edgar (US Regulatory) • 10/12/2021 10:16:44 AM
Notification That Annual Report Will Be Submitted Late (nt 10-k) • Edgar (US Regulatory) • 09/28/2021 10:05:12 AM
More NXEN News
InvestorsHub NewsWire
FEATURED Nutriband Inc. Successfully Obtains Court Verdict for Recovery of Shares Constituting 15% of Its Total Outstanding Shares • Jul 15, 2022 9:55 AM
Green Battery Minerals Reports New Graphic Outcrops On Zone 6 And Channel Sampling • GBMIF • Jul 15, 2022 8:53 AM
VPR Brands Receives Favorable Decision from The US Patent Trial and Appeal Board (PTAB) • VPRB • Jul 14, 2022 7:15 AM
Emerging Markets Report: Win/Win • LMRXF • Jul 13, 2022 11:15 AM
OTC: ILUS, ILUS International (Ilustrato Pictures International Inc) Provides an Updated Revenue Forecast for 2022 • ILUS • Jul 13, 2022 10:49 AM
Metatron Updates Metaverse Marketplace NFTMinthouse.com • MRNJ • Jul 13, 2022 9:30 AM
SOBRsafe Enters Fleet Market with Major Midwestern Food Management Company • SOBR • Jul 13, 2022 9:08 AM
Grove Inc., Chief Executive Officer, Allan Marshall Provides Corporate Update in Letter to Shareholders • GRVI • Jul 13, 2022 8:43 AM
Branded Legacy, Inc. Acquires Astound NMN from Rimrock Gold Corp. • BLEG • Jul 13, 2022 8:30 AM
B2 Digital Sets Company Records, Entertains Crowds at Action Packed B2FS 167, 168, and 169 • BTDG • Jul 13, 2022 7:30 AM
Resgreen Group's Autonomous Mobile Robots Use 2D and 3D LiDAR Systems to Help Navigate Facilities • RGGI • Jul 13, 2022 7:07 AM
Altitude International Holdings, Inc. (ALTD) is under Contract to purchase Club Med Sandpiper Bay's World-Class Property which is to become Altitude's international headquarters upon closing. • ALTD • Jul 12, 2022 1:35 PM
Cannabix Technologies Participates in New Study with Marijuana Breathalyzer technology - Southern United States • BLOZF • Jul 12, 2022 8:45 AM
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System • ONPH • Jul 12, 2022 8:36 AM
EzFill Announces Expansion of Commercial Fleet Business with Addition of New Delivery Vehicles and Launch of New Marketing Campaign • EZFL • Jul 12, 2022 8:09 AM
Start posting your company's news
Only $200 per official company press release!
NXEN
Nexien BioPharma Inc (QB)
0.0633
0.0073 (13.04%)
Volume: 2,260
Day Range: 0.058 - 0.0633
Bid: 0.058
Ask: 0.079
Last Trade Time: 11:30:16 AM EDT
Total Trades: 2
1D
1M
2M
3M
6M
1Y
2Y
3Y
5Y
Chart for Nexien BioPharma Inc (QB)
NXEN Detailed Quote
Get the best-in-class trading platforms that keep getting better with thinkorswim®.
Follow Board
Keyboard Shortcuts
Report TOS Violation
© Copyright 2022
Follow InvestorsHub on Twitter! @investors_hub Like InvestorsHub on Facebook! See the latest blog posts from ADVFN on Medium!
About Us
Terms of Service
Privacy Policy
Advertise With Us
Data Accreditations
Disclaimer
FAQ
Handbook
Q&A Forum
Contact Us
Corporate Solutions
Educational Channel
Stock Market 101
Investor Help Forum
iHub NewsWire
Get InvestorsHub on the iOS App Store
Get InvestorsHub on the Google Play Store
Vertical Aerospace Secures Pre-Delivery Payment Commitment From American Airlines
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
87
|
Created
|
07/15/22
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |